Abbott Agrees to Pay Nearly $385 Million Over Infant Formula Manufacturing Allegations

Abbott Laboratories has agreed to pay nearly $385 million to resolve federal and state allegations involving the manufacture of certain powder infant formula and nutritional therapy products between 2018 and 2022. More than half of infant formula purchased in the United States is paid for through the USDA-funded WIC program, according to federal officials. The settlement resolves allegations only, with no determination of liability. Sheila Fitzgerald/Shutterstock

Abbott Laboratories has agreed to pay nearly $385 million to settle federal and state allegations involving the manufacture of certain powder infant formula and nutritional therapy products, including products purchased through government-funded nutrition programs.

According to the U.S. Department of Justice, Abbott will pay a total of $384,999,040 to resolve allegations stemming from products manufactured at facilities in Sturgis, Michigan, and Casa Grande, Arizona, between January 1, 2018, and December 31, 2022.